Publikationen von S. Ryazanov

Shi, S.; Wagner, J.; Mitteregger-Kretzschmar, G.; Ryazanov, S.; Leonov, A.; Griesinger, C.; Giese, A.: Quantitative real-time quaking-induced conversion allows monitoring of disease-modifying therapy in the urine of prion-infected mice. Journal of Neuropathology and Experimental Neurology 74 (9), S. 924 - 933 (2015)

Levin, J.; Schmidt, F.; Boehm, C.; Prix, C.; Bötzel, K.; Ryazanov, S.; Leonov, A.; Griesinger, C.; Giese, A.: The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathologica 127 (5), S. 779 - 780 (2014)

Wagner, J.; Ryazanov, S.; Leonov, A.; Levin, J.; Shi, S.; Schmidt, F.; Prix, C.; Pan-Montojo, F.; Bertsch, U.; Mitteregger-Kretzschmar, G. et al.; Geissen, M.; Eiden, M.; Leidel, F.; Hirschberger, T.; Deeg, A. A.; Krauth, J.; Zinth, W.; Tavan, P.; Pilger, J.; Zweckstetter, M.; Frank, T.; Baehr, M.; Weishaupt, J. H.; Uhr, M.; Urlaub, H.; Teichmann, U.; Samwer, M.; Bötzel, K.; Groschup, M.; Kretzschmar, H.; Griesinger, C.; Giese, A.: Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathologica 125 (6), S. 795 - 813 (2013)

Buss, S.; Kuebler, L.; Maurer, A.; Schmidt, F.; Leonov, A.; Ryazanov, S.; Giese, A.; Griesinger, C.; Pichler, B. J.; Herfert, K.: In vitro evaluation of small molecule compounds as potential PET tracers targeting a-synuclein. 29th International Symposium on Cerebral Blood Flow, Metabolism and Function / 14th International Conference on Quantification of Brain Function with PET (BRAIN and BRAIN Pet), Yokohama, Japan, 04. Juli 2019 - 07. Juli 2019. Journal of Cerebral Blood Flow and Metabolism 39 (Suppl), S. 530 - 531 (2019)

Antonschmidt, L.; Dervisoglu, R.; Ryazanov, S.; Leonov, A.; Wegstroth, M.; Giller, K.; Becker, S.; Lee , J.; Lal , R.; Eichele, G. et al.; Fischer , A.; Giese, A.; Andreas, L.; Griesinger, C.: The small molecule anle138b shows interaction with alpha-synuclein oligomers in phospholipid membranes. 62nd Annual Meeting of the Biophysical-Society, San Francisco, CA, 17. Februar 2018 - 21. Februar 2018. Biophysical Journal (Suppl), 3 Aufl., S. 560a - 560a (2018)

Sadasivam, S. M.; Ryazanov, S.; Leonov, A.; Roeters, S.; Wouterson, S.; Giese, A.; Griesinger, C.; Killian, J. A.: Effect of the novel amyloid inhibitor "anle145c" on aggregation of islet amyloid polypeptide and how it is modulated by membranes. 60th Annual Meeting of the Biophysical-Society, Los Angeles, CA, 27. Februar 2016 - 02. März 2016. Biophysical Journal 110 (Suppl 1), 3 Aufl., S. 420A - 420A (2016)

Prix, C.; Schmidt, F.; Levin, J.; Schinke, K.; Shi, S.; Ryazanov, S.; Leonov, A.; Högen, T.; Mitteregger-Kretzschmar, G.; Kretzschmar, H. A. et al.; Bötzel, K.; Griesinger, C.; Giese, A.: The oligomer modulator anle138b is effective in the prodromal phase of a transgenic mouse model of Parkinson's disease. Joint Congress of European Neurology, Istanbul, Turkey, 31. Mai 2014 - 03. Juni 2014. European Journal of Neurology 21 (Suppl. 1), S. 170 - 170 (2014)

Kretzschmar, H.; Wagner, J.; Ryazanov, S.; Leonov, A.; Levin, J.; Shi, S.; Prix, C.; Groschup, M.; Griesinger, C.; Giese, A.: Causal therapy of prion and Parkinson's disease with novel inhibitors of protein aggregation. 87th Annual Meeting of the American Association of Neuropathologists, Seattle, WA, 23. Juni 2011 - 26. Juni 2011. Journal of Neuropathology and Experimental Neurology 70 (6), S. 505 - 505 (2011)

Levin, J.; Wagner, J.; Ryazanov, S.; Leonov, A.; Shi, S.; Schmidt, F.; Prix, C.; Bertsch, U.; Mitteregger-Kretzschmar, G.; Geissen, M. et al.; Hischberger, T.; Tavan, P.; Pilger, J.; Zweckstetter, M.; Frank, T.; Baehr, M.; Weishaupt, J.; Uhr, M.; Urlaub, H.; Teichmann, U.; Boetzel, K.; Groschup, M.; Kretzschmar, H. A.; Griesinger, C.; Giese, A.: Causal therapy of Parkinson's disease with anle138b, a novel protein aggregation inhibitor. 15th International Congress of Parkinsons Disease and Movement Disorders, Toronto, CANADA, 2011. Movement Disorders 26 (Supplement 2), S. S21 - S21 (2011)

Giese, A.; Bertsch, U.; Kretzschmar, H.; Habeck, M.; Hirschberger, T.; Tavan, P.; Griesinger, C.; Leonov, A.; Ryazanov, S.; Weber, P.: New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases. WO/2010/00372 (2010)

Albariqi, M. M. H.; Baauw, S. M.G.; Fens, S. J.P.J.; Versteeg, S.; Ryazanov, S.; Leonov, A.; Willemen, H. L.D.M.; Stathonikos, N.; Seychell, R. M.; Saghir, A. E. et al.; Gerritsen, B.; Khemtemourian, L.; Vassallo, N.; Giese, A.; Eijkelkamp, N.; Griesinger, C.; Höppener, J. W. M.: The amyloid oligomer modulator anle138b has disease modifying effects in a human IAPP transgenic mouse model of type 2 diabetes mellitus (hIAPP Ob/Ob mice). bioRxiv (2024)

Saw, R. S.; Buss, S.; Schmidt, F.; Ryazanov, S.; Leonov, A.; Kuebler, L.; Bleher, D.; Papadopoulos, I.; Roeben, B.; Schmidt, F. et al.; Reimold, M.; Bonanno, F.; Grotegerd, A.-K.; Ruf, V.; Dahl, B.; Sandiego, C.; Henry, K.; Fehrenbacher, B.; Schaller, M.; Kahle, P.; Gasser, T.; Brockmann, K.; Reischl, G.; la Fougère, C.; Pichler, B.; Maurer, A.; Griesinger, C.; Giese, A.; Herfert, K.: [¹¹C]MODAG 005 – a novel PET tracer targeting alpha-synuclein aggregates in the brain. Research Square (2024)